Application of genetic scissoring in the management of genetically related diseases
DOI:
https://doi.org/10.31989/dsn.v4i8.1730Abstract
ABSTRACT: CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a groundbreaking tool for genome editing, revolutionizing the management of genetic diseases. Its precision, efficiency, and adaptability enable targeted modification of DNA sequences, offering therapeutic potential for a wide range of inherited disorders. This technology utilizes the Cas9 endonuclease, guided by RNA, to introduce site-specific cuts in the genome, facilitating the correction, disruption, or replacement of genes. Applications include addressing monogenic disorders such as cystic fibrosis, sickle cell anemia, and Duchenne muscular dystrophy, as well as polygenic conditions and diseases linked to somatic mutations, including certain cancers. Furthermore, CRISPR has opened avenues for ex vivo and in vivo gene therapies, including the use of stem cells and viral vectors for effective delivery. While significant ethical and technical challenges remain, such as the risk of unintended genetic modifications and equitable access to therapy, CRISPR represents a paradigm shift in the treatment of genetic diseases. These abstract highlights the current state, challenges, and prospects of CRISPR technology as a transformative tool in precision medicine.
Keywords: CRISPR; precision medicine; monogenic disorders; polygenic conditions
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Dietary Supplements and Nutraceuticals - Online ISSN: 2771-5604
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Originality & Rights Assurance
By submitting, authors confirm the manuscript is original, not under consideration elsewhere, and does not infringe third-party rights. Authors are responsible for obtaining permission to reuse any third-party material.
Copyright & License (CC BY 4.0)
Authors retain copyright and grant Dietary Supplements and Nutraceuticals the right of first publication under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license permits unrestricted use, distribution, adaptation, and reproduction in any medium, including commercial use, provided the original author(s) and source are credited, and any changes are indicated.
Author Sharing/Self-Archiving
Authors may post, share, and redistribute the published article (PDF/HTML) anywhere (institutional repositories, websites, academic networks), with acknowledgment of the original publication in this journal and the DOI.
Correspondence & Post-Publication Dialogue
Correspondence regarding articles published in Dietary Supplements and Nutraceuticals.